Vyome Holdings (HIND) Cash from Financing Activities (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Cash from Financing Activities of $5.3 million for Q1 2026, up 3205.54% year-over-year from $160000.0 in Q1 2025, and up 592.24% quarter-over-quarter from $764020.0 in Q4 2025.
Vyome Holdings (HIND) Cash from Financing Activities (2015 - 2026) Analysis & Trends
Vyome Holdings' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at $5.3 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 3205.54% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $13.8 million (up 118.97% YoY), while the FY2025 annual figure was $8.7 million, up 1140.05% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $5.3 million, up from $764020.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $10.2 million in Q1 2023, with the low at -$2.2 million in Q3 2025.
- The 5-year median for Cash from Financing Activities is $638000.0 (2022), against an average of $2.5 million.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities slumped 11366.67% in 2023, then soared 3205.54% in 2026.
- Vyome Holdings' Cash from Financing Activities stood at $638000.0 in 2022, then surged by 755.96% to $5.5 million in 2023, then slumped by 99.02% to $53466.0 in 2024, then surged by 1328.98% to $764020.0 in 2025, then surged by 592.24% to $5.3 million in 2026.
- Business Quant data shows HIND's Cash from Financing Activities at $5.3 million in Q1 2026, $764020.0 in Q4 2025, and -$2.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | -3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,000.00 |
| Jun 30, 2026 | -3,000.00 |
| Mar 31, 2026 | 5.29 Mn |
| Mar 31, 2026 | 5.29 Mn |
| Dec 31, 2025 | 764,020.00 |
| Dec 31, 2025 | 764,020.00 |
| Sep 30, 2025 | -2.16 Mn |
| Sep 30, 2025 | -2.16 Mn |
| Jun 30, 2025 | 9.89 Mn |
| Jun 30, 2025 | 9.89 Mn |
| Mar 31, 2025 | 160,000.00 |
| Mar 31, 2025 | 160,000.00 |
| Dec 31, 2024 | 53,466.00 |
| Dec 31, 2024 | 53,466.00 |
| Sep 30, 2024 | 620,485.00 |
| Sep 30, 2024 | 620,485.00 |
| Dec 31, 2023 | 5.46 Mn |
| Dec 31, 2023 | 5.46 Mn |
| Sep 30, 2023 | -338,000.00 |
| Sep 30, 2023 | -338,000.00 |